For research use only. Not for therapeutic Use.
PTX80 is a first-in-class inhibitor of protein degradation by targeting the autophagy receptor p62/SQSTM1. PTX80 binds to p62, inducing a decrease in soluble p62 and formation of insoluble p62 aggregates, and failure of polyubiquitinated proteins to colocalize with p62. PTX80 induces proteotoxic stress and activation of unfolded protein response, which, in turn, leads to apoptosis.
KEYWORDS: PTX80 | p62/SQSTM1 ligand | PTX 80 | PTX-80 | CAS [2376297-69-5] | [2376297-70-8] | [2376297-71-9] | Ubiquitin | Inhibitor | Proteins | Sequestosome 1 | UPR
| Catalog Number | I047687 |
| CAS Number | 2376297-69-5 |
| Molecular Formula | C26H26N4O3S |
| Purity | ≥95% |
| IUPAC Name | 4-[(E)-[(5E)-5-[(4-cyanophenyl)methylidene]-1-[3-(dimethylamino)propylsulfonyl]-4-oxopiperidin-3-ylidene]methyl]benzonitrile |
| InChI | InChI=1S/C26H26N4O3S/c1-29(2)12-3-13-34(32,33)30-18-24(14-20-4-8-22(16-27)9-5-20)26(31)25(19-30)15-21-6-10-23(17-28)11-7-21/h4-11,14-15H,3,12-13,18-19H2,1-2H3/b24-14+,25-15+ |
| SMILES | CN(CCCS(=O)(=O)N1C/C(=C\C2=CC=C(C=C2)C#N)/C(=O)/C(=C/C3=CC=C(C=C3)C#N)/C1)C |
| Reference | O Kalid et al. PTX80, A Novel Compound Targeting the Autophagy Receptor p62/SQSTM1 for Treatment of Cancer. Chem Biol Drug Des. 2022 Mar 24. |
